Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.69 |
| ▸ | CA1 | P00915 | 1/20 | 0.69 |
| ▸ | CA2 | P00918 | 1/20 | 0.69 |
| ▸ | CA7 | P43166 | 1/20 | 0.69 |
| ▸ | CA9 | Q16790 | 1/20 | 0.69 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.58 |
| ▸ | MMP1 | P03956 | 2/20 | 0.58 |
| ▸ | MMP2 | P08253 | 1/20 | 0.58 |
| ▸ | MMP9 | P14780 | 1/20 | 0.58 |
| ▸ | MMP14 | P50281 | 1/20 | 0.58 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.58 |
| ▸ | MAOB | P27338 | 7/20 | 0.56 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.56 |
| ▸ | APP | P05067 | 1/20 | 0.56 |
| ▸ | PTPRZ1 | P23471 | 1/20 | 0.55 |
| ▸ | AR | P10275 | 1/20 | 0.55 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | CASP3 | P42574 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3280133 | 0.83 | CA12 (0.68) | CA12CA1CA2CA7CA9 | |
| SCHEMBL15367675 | 0.82 | MAOB (0.59) | CA12CA1CA2CA7CA9 | |
| SCHEMBL6949459 | 0.82 | CA12 (0.71) | CA12CA1CA2CA7CA9 | |
| SCHEMBL22193397 | 0.82 | MAOB (0.59) | CA12CA1CA2CA7CA9 | |
| SCHEMBL5443121 | 0.82 | CA12 (0.71) | CA12CA1CA2CA7CA9 | |
| SCHEMBL23306906 | 0.82 | RXRA (0.59) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1424430 | 0.81 | CA12 (0.70) | CA12CA1CA2CA7CA9 | |
| SCHEMBL27550091 | 0.80 | MAOB (0.80) | CA12CA1CA2CA7CA9 | |
| Hydrochloric Acid SCHEMBL28119647 | 0.80 | CA12 (0.68) | CA12CA1CA2CA7CA9 | |
| SCHEMBL7857588 | 0.79 | SOS1 (0.63) | CA1CA2MMP1MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1181286-B1 | 3-(ARYLSULFONYLAMINO)-TETRAHYDROPYRAN-3-CARBOXYLIC ACID HYDROXAMIDES | PFIZER PROD INC (US) | 2003-11-12 | — | — | EP | disclosed |
| EP-1181285-B1 | 3-(ARYLSULFONYLAMINO)-TETRAHYDROFURAN-3-CARBOXYLIC ACID HYDROXAMIDES | PFIZER PROD INC (US) | 2003-10-08 | — | — | EP | disclosed |
| EP-0977733-B1 | ARYLSULFONYLAMINO HYDROXAMIC ACID DERIVATIVES | PFIZER PROD INC (US) | 2003-09-03 | — | — | EP | disclosed |
| US-6599890-B1 | Inhibitors of matrix metalloproteinases or the production of tumor necrosis factor | PFIZER INC | 2003-07-29 | — | — | US | disclosed |
| EP-1070058-B1 | (4-ARYLSULFONYLAMINO)-TETRAHYDROPYRAN-4-CARBOXYLIC ACID HYDROXAMIDES | PFIZER PROD INC (US) | 2003-05-02 | — | — | EP | disclosed |
| EP-1181285-A2 | 3-(ARYLSULFONYLAMINO)-TETRAHYDROFURAN-3-CARBOXYLIC ACID HYDROXAMIDES | Pfizer Products Inc. (US) | 2002-02-27 | — | — | EP | disclosed |
| EP-1181286-A1 | 3-(ARYLSULFONYLAMINO)-TETRAHYDROPYRAN-3-CARBOXYLIC ACID HYDROXAMIDES | Pfizer Products Inc. (US) | 2002-02-27 | — | — | EP | disclosed |
| US-6342521-B1 | DRUGS FOR TREATMENT OF ARTHRITIS | PFIZER INC. | 2002-01-29 | — | — | US | disclosed |
| US-20020006920-A1 | Arylsulfonylamino hydroxamic acid derivatives | ROBINSON RALPH PELTON (US) | 2002-01-17 | — | — | US | disclosed |
| US-6303636-B1 | FOR THERAPY OF ARTHRITIS, CANCER, TISSUE ULCERATION, RESTENOSIS, PERIODONTAL DISEASE, EPIDERMOLYSIS BULLOSA, SCIERITIS, SEPSIS, SEPTIC SHOCK AND OTHER DISEASES INVOLVING THE PRODUCTION OF TUMOR NECROSIS FACTOR | PFIZER INC | 2001-10-16 | — | — | US | disclosed |
| EP-1070058-A1 | (4-ARYLSULFONYLAMINO)-TETRAHYDROPYRAN-4-CARBOXYLIC ACID HYDROXAMIDES | Pfizer Products Inc. (US) | 2001-01-24 | — | — | EP | disclosed |
| WO-2000073295-A1 | 3-(ARYLSULFONYLAMINO)-TETRAHYDROPYRAN-3-CARBOXYLIC ACID HYDROXAMIDES | PFIZER PRODUCTS INC. (US) | 2000-12-07 | — | — | WO | disclosed |
| WO-2000073294-A2 | 3-(ARYLSULFONYLAMINO)-TETRAHYDROFURAN-3-CARBOXYLIC ACID HYDROXAMIDES | PFIZER PRODUCTS INC. (US) | 2000-12-07 | — | — | WO | disclosed |
| US-6087392-A | A METALLOPROTEINASE INHIBITORS FOR INHIBITING MAMMALIAN REPROLYSIN | PFIZER INC. (US) | 2000-07-11 | — | — | US | disclosed |
| CN-1247531-A | Arylsulfonyl hydroxamic acid derivatives | PFIZER (US) | 2000-03-15 | — | — | CN | disclosed |
| EP-0977733-A1 | ARYLSULFONYLAMINO HYDROXAMIC ACID DERIVATIVES | Pfizer Products Inc. (US) | 2000-02-09 | — | — | EP | disclosed |
| EP-0960098-A1 | ARYLSULFONYL HYDROXAMIC ACID DERIVATIVES | PFIZER INC. (US) | 1999-12-01 | — | — | EP | disclosed |
| WO-1999052889-A1 | (4-ARYLSULFONYLAMINO)-TETRAHYDROPYRAN-4-CARBOXYLIC ACID HYDROXAMIDES | PFIZER PRODUCTS INC. (US) | 1999-10-21 | — | — | WO | disclosed |
| WO-1998034918-A1 | ARYLSULFONYL HYDROXAMIC ACID DERIVATIVES | PFIZER INC. (US) | 1998-08-13 | — | — | WO | disclosed |
| WO-1998033768-A1 | ARYLSULFONYLAMINO HYDROXAMIC ACID DERIVATIVES | PFIZER PRODUCTS INC. (US) | 1998-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020006920-A1 | Arylsulfonylamino hydroxamic acid derivatives | MMP8, MMP1, MMP10 | CA12 3958/4885CA1 2612/4885CA2 2445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.